ClinicalTrials.gg
RecruitingNCT06405126Optiek 2-0Updated May 8, 2024

Validation of a Machine Learning Predictive Model to Distinguish Post-capillary Pulmonary Hypertension

An observational study in Pulmonary Hypertension, Pulmonary Arterial Hypertension and HFpEF - Heart Failure With Preserved Ejection Fraction, sponsored by KU Leuven. Recruiting at 4 sites in Belgium. Open to participants aged 18 Years and older. Per ClinicalTrials.gov, last updated 2024-05-08.

Primary conditionPulmonary Arterial HypertensionRegistry: Hypertension, PulmonaryReclassifiedWhy we changed it
Registry
Hypertension, Pulmonary — the first condition term the registry derived for this study.
ClinicalTrials.gg
Pulmonary Arterial Hypertension
Why
  1. The study's listed conditions name Pulmonary Arterial Hypertension, a narrower term within Hypertension, Pulmonary.
Confidence
High: the new condition is named in the study's own listed conditions. Of 351 hand-checked studies reclassified this way, 68% were exactly right and 84% in the right disease family; the registry's first term was right for 5% (measured 2026-10-21). How we classify →
Wrong?
Tell us the study's main condition →

Sponsored by KU Leuven · Observational

How we know

From the registry’s dates

  • Primary completion was expected by Aug 2025, 1 year 3 months ago, but the record still lists the study as recruiting.
  • Started Feb 2024; still recruiting 2 years 9 months later.

Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →

Study type
Observational
Model
Cohort
Time perspective
Prospective
Enrollment
100
Ages
18 Years and older
Sex
All
01

Where this study stands

Counted across the records on this site · 2026-11-22

Among 65 studies in Pulmonary Arterial Hypertension with a site in Belgium — 10 open to participants now, 14 under way, 7 of them phase 3. Pulmonary Arterial Hypertension · Belgium.

Started
2024
with 2 others
Observational
6 of 65
3 open now
Primary completion
2025-08
later than 1 of 13 live
Registered
61st of 65
by date

Among the 65 studies in Pulmonary Arterial Hypertension with a site in Belgium, this one is one of 3 that started in 2024, is one of 6 observational ones, reaches primary completion later than 1 of the 13 other live ones, and was the 61st registered.

Pulmonary Arterial Hypertension

701 studies on the registry are indexed under Pulmonary Arterial Hypertension; 141 are open to participants now.

Browse Pulmonary Arterial Hypertension studies →

Open to participants now

10 of the 65 studies in Pulmonary Arterial Hypertension with a site in Belgium are open now. Recruiting first, the newest first:

4 more — sign in →

All 10 open studies →

A study can be open while its sites in Belgium have not opened yet or have stopped. Only those recruiting at a site in Belgium →

Who these studies take

Of the 90 Pulmonary Arterial Hypertension studies recruiting now, 51 (57%) set no upper age limit and 24 (27%) stop at 75 or younger; 18 take children under 18; 11 take healthy volunteers.

This study: 18 Years and older · all sexes · no healthy volunteers.

The full table on the hub →

This tab as a report to print or save as PDF → With an account.

Was this useful?
Get alerts for this landscapeDownload CSVNarrow it in search →With an account: a weekly mail of what changed among 65 studies in Pulmonary Arterial Hypertension with a site in Belgium, or all of them as a file.
02

Study summary

In this study the diagnostic accuracy of a diagnostic tool for the diagnosis of post-capillary pulmonary hypertension will be investigated.

The diagnostic tool was designed based on artificial intelligence, using machine learning on a database of 344 patients with group 1 or group 2 pulmonary hypertension. The tool uses 20 non-invasive parameters which are derived from laboratory results, ECG, echocardiography and spirometry. Based on these parameters, the predictive tool estimates the probability of group 2 pulmonary hypertension.

During this clinical study, patients with an intermediate or high suspicion of pulmonary hypertension, with an indication for a diagnostic right heart catheterization, will be included. Patients with risk factors for group 3, 4 or 5 pulmonary hypertension will be excluded.

The necessary parameters to run the predictive model will be extracted from the patients medical file. Patients will undergo a standard of care right heart catheterization (gold standard). Afterwards the results of the predictive model will be compared to those of the right heart catheterization, to allow the assessment of the sensitivity, specificity, positive and negative predictive value of the predictive tool.

03

Conditions studied

  • Pulmonary Hypertension
  • Pulmonary Arterial Hypertension
  • HFpEF - Heart Failure With Preserved Ejection Fraction

Browse trials for

Keywords

  • pulmonary hypertension
  • pulmonary arterial hypertension
  • post-capillary pulmonary hypertension
  • HFpEF
  • artificial intelligence
  • diagnostic tool
  • machine learning
  • non-invasive diagnosis
04

In context

Pulmonary Arterial Hypertension Reclassified

701 studies on the registry are indexed under Pulmonary Arterial Hypertension; 141 are open to participants now.

This study's planned enrollment of 100 is close to the median of 104 across 181 observational studies indexed under Pulmonary Arterial Hypertension.

Browse Pulmonary Arterial Hypertension studies →

Lead sponsor

KU Leuven is the lead sponsor of 373 studies on the registry; 65 are open to participants now.

Compared within Pulmonary Arterial Hypertension, this study's primary condition as ClinicalTrials.gg classifies it; the registry's first condition term is Hypertension, Pulmonary. The counts are of registry records indexed under each term, refreshed daily. How we classify →

05

Who can participate

Ages eligible
18 Years and older
Sexes eligible
All
Accepts healthy volunteers
No
Sampling method
Probability sample

Study population

Patients with an intermediate to high probability of pulmonary hypertension based on an echocardiography. Patients with a probability of group 3, 4 or 5 pulmonary hypertension will be excluded.

Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.

Inclusion criteria

  1. Voluntary written of the participant or their legally authorized representative has been obtained prior to any screening procedures
  2. Male or female patients of at least 18 years old.
  3. Availability of the results of a basic work-up:

    1. Medical history, demographic information and clinical information (including )
    2. Laboratory tests including , hematocrit and uric acid
    3. Pulmonary function tests
    4. Echocardiography
  4. Intermediate to high probability of PH based on echocardiography according to the 2022 ESC/ERS guidelines (see Figure 2 and Table 2). (1)
  5. Indication for RHC according to ESC/ERS 2022 guidelines. (1)

Exclusion criteria

Exclusion Criteria:

  1. Evidence of significant pulmonary comorbidity based on abnormal pulmonary function tests ( below 60%) or aberrant lung parenchyma more than mild on radiological imaging.
  2. Perfusion defects and ventilation mismatch on a recent V/Q scan.
  3. Arterial perfusion defects on a recent thoracic CT angiography.
  4. The following comorbidities associated with group 1 PH:

    1. Connective tissue disease
    2. infection
    3. Portal hypertension
    4. Congenital heart disease
  5. The following comorbidities associated with group 5 PH:

    1. Hematological disorders such as chronic hemolytic anemia or myeloproliferative disorders.
    2. Systemic and metabolic disorders such as pulmonary Langerhans cell histiocytosis, Gaucher disease, glycogen storage diseases, neurofibromatosis or sarcoidosis.
    3. Chronic renal failure ( below 30 ml/min) with or without hemodialysis
    4. Fibrosing mediastinitis
Terms in these criteria, in plain language(7)

Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.

Informed consent

Before you join, the study team explains what taking part involves — its purpose, what happens, the risks and possible benefits — and answers your questions, so you can decide freely. Consent is usually recorded on a form (the informed consent form, ICF) signed by you or, where the law allows, by someone legally authorized to decide for you.

You can keep asking questions during the study, you are told of new information that matters, and you can choose to leave at any time.

BMI (body mass index)

Weight in kilograms divided by height in metres squared. Example: 70 kg and 1.75 m gives 70 ÷ (1.75 × 1.75) ≈ 22.9.

What counts as overweight or obesity differs between countries (some use lower cut-offs), so go by the range the study states.

Hemoglobin (Hb)

The protein in red blood cells that carries oxygen. A low level is anemia, which can cause tiredness and breathlessness. Measured in g/dL or g/L (9 g/dL is 90 g/L).

ECG (electrocardiogram)

A recording of the heart’s electrical activity, taken with stickers on the chest, arms and legs. It takes a few minutes and does not hurt.

FEV1

From a breathing test (spirometry): how much air you can blow out in the first second. Often given as a percentage of what is expected for your age, height and sex.

HIV

The human immunodeficiency virus, which weakens the immune system.

Many studies now accept people whose HIV is controlled on treatment, judged by the viral load and the CD4 count. Check the limits this study sets.

GFR and eGFR (kidney filtering)

GFR (glomerular filtration rate) is how much blood the kidneys filter each minute. It is usually estimated from a blood test — eGFR, by formulas such as CKD-EPI or MDRD — and some studies ask for it to be measured directly instead. Usually given in mL/min/1.73 m².

Check the method, the units and the minimum the study states. A value of 90 or above is in the normal-or-high range, but kidney damage can show in other tests too.

06

Study design

Observational model
Cohort
Time perspective
Prospective
Enrollment
100 participants (estimated)
Patient registry
No

Interventions

  • Diagnostic testOptiek predictive model

    Patient data will be extracted to run the predictive model, which will estimate the probability of group 2 pulmonary hypertension. However the results of the model will have no diagnostic or therapeutic implications in this phase of the investigation.

07

What researchers measure

Primary outcomes

  1. Diagnostic accuracy of the Optiek model

    sensitivity, specificity, positive and negative predictive value of the model compared to a right heart catheterization (gold standard)

    Time frame: 18 months

Secondary outcomes

  1. Number of right heart catheterizations which could have been avoided

    The number of avoidable rght heart catheterizations will be derived from the sensitivity of the model.

    Time frame: 18 months

  2. Right heart catheterization related adverse events

    All subsequent adverse events will be registered in the eCRF.

    Time frame: 18 months

  3. Feasibility of the implementation of the Optiek model in clinical practice

    The feasibility will be assessed using a questionnaire adressed to the physicians using the model.

    Time frame: 18 months

08

Study locations

4 of 4 sites recruiting
09

Timeline

Tracking since Sep 25, 2026
ElapsedEstimatedEstimated, not yet reachedSimilar studies: half by the dot; the band is the middle halfHalf of similar studies reached it by the dot; the band is the middle half, from a quarter to three quarters

Started Feb 2024 (actual). Primary completion is estimated for Aug 2025, 18 months after the start.

Of 64 non-industry observational studies under Pulmonary Arterial Hypertension, half reached primary completion within 60 months of starting (the median), counting those still running; a quarter within 31. This study's planned 18 months is below that.

Counting every sponsor, half of 85 studies reached it within 58 months; a quarter within 30 and three quarters within 93.

How these figures are worked out, and which studies are left out of them.

Registered
Apr 16, 2024
First posted
May 8, 2024
StartActual
Feb 21, 2024
Primary completionEst.
Aug 2025
CompletionEst.
Feb 2026
Last update
May 8, 2024
What these dates mean
Start.
When the first participant enrolled; while estimated, when the study expects to open to recruitment.
Primary completion.
When the last participant was examined or treated to collect data for the study's main question, its primary outcome. A study that stopped early gives the date its data collection stopped.
Completion.
When the last participant's last visit took place, for every outcome, secondary ones and side effects included: the end of the study. Often later than primary completion, sometimes the same day.
Actual and Est.
Actual means the registry says the date has happened. Est. (estimated) is a date the sponsor plans or expects. It can still move, and the sponsor is expected to change it to actual once it has passed.
No changes since tracking began. The registry record was last updated on May 8, 2024, before this site started recording changes on Sep 25, 2026. Its history is on ClinicalTrials.gov ↗
10

Registry details

Key details

Study ID
NCT06405126
Lead sponsor
KU Leuven
Collaborators
Research Foundation Flanders
Responsible party
Marion DELCROIX (MD PhD, KU Leuven) — Principal investigator
First posted
May 8, 2024
Start date
Feb 21, 2024
Primary completion
Aug 2025 (estimated)
Completion
Feb 2026 (estimated)
Last update
May 8, 2024

Study contacts

Laura Hardy, MD
Contact
laura.hardy@uzleuven.be
+3216338917

Oversight

Data monitoring committee
No
FDA-regulated drug
No
FDA-regulated device
No
View the source record on ClinicalTrials.gov ↗

Interested in this study?

Eligibility is decided by the study team. Share this record with your doctor or contact the team directly.

Contact study team

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Start the discussion